Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
130
Trial Sponsor
Clinical Trial Start Date
March 11, 2021
0Primary Completion Date
May 28, 2021
0Study Completion Date
May 28, 2021
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Other0
Drug0
Intervention Name
Placebo0
Emricasan0
Interventional Trial Phase
Phase 10
Official Name
Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-190
Last Updated
January 4, 2022
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
Triple0
Masked Party
Care Provider0
Participant0
Investigator0
Study summary
Treatments for COVID-19 are urgently needed. Emricasan (EMR) is a pan caspase inhibitor. Caspase-1 plays a role in a form of cell death called pyroptosis. EMR inhibits pyroptosis. The Investigators have shown that peripheral blood lymphocytes of COVID-19 patients overexpress caspase-1, providing evidence for pyroptosis. A recent European study corroborate the Investigators finding as they have shown evidence for the activation of the inflammasome in COVID-19.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
